UBS AM’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,109
| Closed | -$356K | – | 2648 |
|
|
2023
Q2 | $356K | Hold |
6,109
| – | – | ﹤0.01% | 2424 |
|
|
2023
Q1 | $356K | Buy |
6,109
+584
| +11% | +$28.8K | ﹤0.01% | 2424 |
|
|
2022
Q4 | $282K | Buy |
5,525
+724
| +15% | +$50.2K | ﹤0.01% | 2350 |
|
|
2022
Q3 | $393K | Buy |
4,801
+50
| +1% | +$3.73K | ﹤0.01% | 2426 |
|
|
2022
Q2 | $321K | Buy |
4,751
+610
| +15% | +$56K | ﹤0.01% | 2459 |
|
|
2022
Q1 | $458K | Sell |
4,141
-1,974
| -32% | -$246K | ﹤0.01% | 2488 |
|
|
2021
Q4 | $590K | Buy |
6,115
+489
| +9% | +$48.7K | ﹤0.01% | 2487 |
|
|
2021
Q3 | $491K | Hold |
5,626
| – | – | ﹤0.01% | 2510 |
|
|
2021
Q2 | $871K | Buy |
5,626
+1,918
| +52% | +$278K | ﹤0.01% | 2278 |
|
|
2021
Q1 | $585K | Sell |
3,708
-484
| -12% | -$102K | ﹤0.01% | 2330 |
|
|
2020
Q4 | $973K | Buy |
4,192
+841
| +25% | +$195K | ﹤0.01% | 2008 |
|
|
2020
Q3 | $734K | Sell |
3,351
-113
| -3% | -$27.6K | ﹤0.01% | 1962 |
|
|
2020
Q2 | $984K | Sell |
3,464
-4
| -0.1% | -$1.18K | ﹤0.01% | 1819 |
|
|
2020
Q1 | $999K | Sell |
3,468
-877
| -20% | -$242K | ﹤0.01% | 1693 |
|
|
2019
Q4 | $1.25M | Buy |
4,345
+736
| +20% | +$160K | ﹤0.01% | 1810 |
|
|
2019
Q3 | $521K | Buy |
3,609
+1,811
| +101% | +$246K | ﹤0.01% | 2272 |
|
|
2019
Q2 | $162K | Buy |
1,798
+904
| +101% | +$72.6K | ﹤0.01% | 2591 |
|
|
2019
Q1 | $78.3K | Hold |
894
| – | – | ﹤0.01% | 2582 |
|
|
2018
Q4 | $126K | Buy |
+894
| New | +$151K | ﹤0.01% | 2493 |
|
|
2016
Q4 | – | Sell |
-700
| Closed | -$102K | – | 2576 |
|
|
2016
Q3 | $102K | Hold |
700
| – | – | ﹤0.01% | 2573 |
|
|
2016
Q2 | $70K | Hold |
700
| – | – | ﹤0.01% | 2598 |
|
|
2016
Q1 | $94K | Hold |
700
| – | – | ﹤0.01% | 2575 |
|
|
2015
Q4 | $139K | Hold |
700
| – | – | ﹤0.01% | 2619 |
|
|
2015
Q3 | $111K | Hold |
700
| – | – | ﹤0.01% | 2598 |
|
|
2015
Q2 | $286K | Sell |
700
-6,740
| -91% | -$2.91M | ﹤0.01% | 2396 |
|
|
2015
Q1 | $3.42M | Sell |
7,440
-47
| -0.6% | -$20.3K | ﹤0.01% | 1154 |
|
|
2014
Q4 | $4.2M | Buy |
7,487
+6,947
| +1,286% | +$3.95M | ﹤0.01% | 1081 |
|
|
2014
Q3 | $283K | Buy |
+540
| New | +$305K | ﹤0.01% | 2175 |
|
|
2014
Q2 | – | Sell |
-3,107
| Closed | -$1.44M | – | 2569 |
|
|
2014
Q1 | $1.44M | Sell |
3,107
-13
| -0.4% | -$6.59K | ﹤0.01% | 1439 |
|
|
2013
Q4 | $1.07M | Buy |
+3,120
| New | +$862K | ﹤0.01% | 1498 |
|
Other funds holding KPTI
APM
PAI
UBS AM's KPTI Position: Q3 2023 in Review
UBS AM sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 6,109 shares — an estimated $356K sold.
UBS AM first reported a position in KPTI in Q4 2013 and held it in 30 quarters. The position peaked at $4.2M in Q4 2014. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.
- UBS AM reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
- UBS AM sold 6,109 Karyopharm Therapeutics shares in Q3 2023, an estimated $356K.
- UBS AM first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 30 quarters.
- UBS AM's Karyopharm Therapeutics position peaked at $4.2M in Q4 2014.
- 118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.
Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.